Abstract :
BACKGROUND: Dual antiplatelet therapy (APD) is the cornerstone of management of coronary artery disease in
coronary interventions. The resistance pattern against clopidogrel in our influenza is unknown. The aim of this
study was to evaluate the frequency of resistance / hypoactivation to Clopidogrel after percutaneous coronary
intervention (PCI) in the Pakistani population.
METHODS: The study was conducted in the Mayo hospital, Lahore for 1 year period From June 2016 to June
2017. After informed consent, patients who underwent PCI were received 4 weeks ago. All patients received 600 mg
Clopidogrel 4 to 6 hours before PCI and received 75 mg Aspirin and Clopidogrel 75 mg twice daily in addition to
their routine medications. Venous blood samples were collected from all selected patients and a blocking analysis
test was performed on P2Y12. The test has a "Closing Time" measured within the seconds. Patients were labeled as
resistant (closing time 225 seconds) based on this time. Demographic data and coronary risk factors were observed for all
patients.
Findings: Fifty patients (38 males and 12 females) were studied. Fifteen (30%) patients responded completely to
Clopidogrel-resistant, 5 (10%) hypertensive and 30 (60%) closing time criteria. None of them had a clinically
significant coronary event 4 weeks after PCI.
CONCLUSION: More than 1/3 of the post-PCI patients are more likely to be resistant or hypoactive to clopidogrel.
Keywords: Clopidogrel, P2Y12 platelet antiaggregation.
Keyword :
Clopidogrel, P2Y12 platelet antiaggregation.